While the molecular mechanisms underlying the contribution of PrPC to tumor resistance are poorly understood, the disruption of the STI1 binding to PrPC was recently shown to impair glioblastoma growth (150), suggesting that cancer cells may usurp the cytoprotective activity of PrPC. The gene discussed is PRNP; the disease is neoplasm.